Stella Diagnostics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLDX research report →
Companywww.stelladx.com
Stella Diagnostics, Inc. , a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients' tissue to determine if the disease is stable, progressing, or turning cancerous.
- CEO
- David Seaburg
- IPO
- 2021
- Employees
- 2
- HQ
- Salt Lake City, UT, US
Price Chart
Valuation
- Market Cap
- $1.37M
- P/E
- -1.04
- P/S
- 0.77
- P/B
- -0.16
- EV/EBITDA
- -3.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -40.44%
- Op Margin
- -196.67%
- Net Margin
- -227.47%
- ROE
- 17.12%
- ROIC
- 24.37%
Growth & Income
- Revenue
- $1.78M · 0.00%
- Net Income
- $-4,057,706 · -228.38%
- EPS
- $-0.01 · -277.42%
- Op Income
- $-3,447,083
- FCF YoY
- -2151.47%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- -0.27
- Avg Volume
- 87
Get TickerSpark's AI analysis on SLDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SLDX Coverage
We haven't published any research on SLDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLDX Report →